Island Pharmaceuticals is a reputable drug research and repurposing company that is dedicated to developing preventative and therapeutic drugs for viral infections. With a focus on addressing unmet medical needs, their lead asset ISLA-101, initially developed by their subsidiary, Isla Pharmaceuticals, is a drug with a proven safety profile. Island Pharmaceuticals has repurposed ISLA-101 to effectively prevent and treat diseases caused by mosquito-borne viruses, such as dengue fever and Zika.

Dengue fever, affecting millions worldwide, remains a significant challenge due to the lack of specific pharmaceutical treatments and limited accessibility of existing vaccines. By repurposing ISLA-101, Island Pharmaceuticals aims to provide a much-needed solution to combat these devastating diseases. With their promising clinical program, which has minimized risks, Island Pharmaceuticals is progressing towards Phase II studies.

For more information and updates, visit their website at www. islandpharmaceuticals. com